Arcus Biosciences ROE 2017-2022 | RCUS
Current and historical return on equity (ROE) values for Arcus Biosciences (RCUS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Arcus Biosciences ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2022-12-31 |
$-0.27B |
$0.66B |
-36.83% |
| 2022-09-30 |
$0.08B |
$0.70B |
10.37% |
| 2022-06-30 |
$0.07B |
$0.75B |
9.15% |
| 2022-03-31 |
$0.06B |
$0.80B |
8.32% |
| 2021-12-31 |
$0.05B |
$0.84B |
7.98% |
| 2021-09-30 |
$-0.28B |
$0.54B |
-48.21% |
| 2021-06-30 |
$-0.20B |
$0.61B |
-34.37% |
| 2021-03-31 |
$-0.17B |
$0.67B |
-31.40% |
| 2020-12-31 |
$-0.12B |
$0.50B |
-30.45% |
| 2020-09-30 |
$-0.09B |
$0.54B |
-27.54% |
| 2020-06-30 |
$-0.11B |
$0.43B |
-49.18% |
| 2020-03-31 |
$-0.10B |
$0.14B |
-55.96% |
| 2019-12-31 |
$-0.09B |
$0.16B |
-44.74% |
| 2019-09-30 |
$-0.08B |
$0.18B |
-38.51% |
| 2019-06-30 |
$-0.07B |
$0.20B |
-30.70% |
| 2019-03-31 |
$-0.06B |
$0.22B |
-22.99% |
| 2018-12-31 |
$-0.05B |
$0.24B |
-19.96% |
| 2018-09-30 |
$-0.05B |
$0.25B |
-22.15% |
| 2018-06-30 |
$-0.06B |
$0.26B |
-37.28% |
| 2018-03-31 |
$-0.06B |
$0.27B |
-56.06% |
| 2017-12-31 |
$-0.05B |
$0.15B |
-137.66% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.194B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
